Genetics and Hepatitis C Virus
Recent Findings from A. Mangia and Co-Authors Highlight Research in Genetics and Hepatitis C Virus
Published in Hepatitis Weekly, February 14th, 2011
2011 FEB 14 -- "The drugs currently licensed for the treatment of hepatitis C are Peg-Interferon (PEG-IFN) and ribavirin. In recent years, the recommendation to treat hepatitis C virus genotype 2-and 3-infected patients with a fixed 800 mg/day dose of ribavirin in combination with PEG-IFN and for just 24 weeks has been challenged by the concept of tailoring the length of therapy according to on-treatment viral response," investigators in San Giovanni Rotondo, Italy report.
"Therefore, the objective of the present review was to highlight the different designs of the studies on short treatment duration and the role of wk4-R as a predictor of sustained...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2011-02-14)
More Articles from Hepatitis Weekly
- Clinical Science
Findings from Chinese PLA General Hospital, Department of Clinical Biochemistry Advance Knowledge in Clinical Science - Hepatitis C Virus
New Findings from University of Washington, Puget Sound Blood Center Describe Advances in Hepatitis C Virus - HIV/AIDS
New HIV/AIDS Study Findings Have Been Reported by N.I. Rallon and Colleagues - Hepatitis B Virus
New Hepatitis B Virus Research from National Taiwan University Described - Hepatitis C Virus
New Hepatitis C Virus Research from Hellenic Pasteur Institute Described - Chronic Hepatitis C Virus
Recent Findings in Chronic Hepatitis C Virus Described by Researchers from University of Paris - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
